InsiderTrades.com logo
Juliette Berangere Audet net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Juliette Audet Biography and Net Worth

Insider of NewAmsterdam Pharma

Juliette Audet is the CBO of NewAmsterdam Pharma. She was most recently a Partner at the life science venture capital firm Forbion where she was part of the team that built NewAmsterdam Pharma. She served as a NewAmsterdam Pharma Board Member from the company’s inception to her transition to the executive team. Before that, Juliette was a Principal at the Novartis Venture Fund, based in Cambridge, Massachusettes, and prior to this, she was a Senior Manager of Strategy at Novartis AG. Juliette spent the first part of her career in management consulting at McKinsey and Company, focusing on pharma and biotech, based out of its Swiss and New York offices. Juliette holds an MBA from Harvard Business School and an MSc in physics from Lausanne, Swiss Federal Institute of Technology.

What is Juliette Berangere Audet's net worth?

The estimated net worth of Juliette Berangere Audet is at least $25,767.36 as of September 26th, 2024. Ms. Audet owns 1,104 shares of NewAmsterdam Pharma stock worth more than $25,767 as of March 18th. This net worth approximation does not reflect any other assets that Ms. Audet may own. Additionally, Ms. Audet receives an annual salary of $45,620.00 as Insider at NewAmsterdam Pharma. Learn More about Juliette Berangere Audet's net worth.

How old is Juliette Berangere Audet?

Ms. Audet is currently 37 years old. There are 6 older executives and no younger executives at NewAmsterdam Pharma. The oldest executive at NewAmsterdam Pharma is Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D., Founder, Chief Scientific Officer, Member of Executive Board & Director, who is 70 years old. Learn More on Juliette Berangere Audet's age.

What is Juliette Berangere Audet's salary?

As the Insider of NewAmsterdam Pharma, Ms. Audet earns $45,620.00 per year. There are 3 executives that earn more than Ms. Audet. The highest earning executive at NewAmsterdam Pharma is Dr. Michael Harvey Davidson FACC, Facp., M.D., CEO, President, Executive Board Member & Director, who commands a salary of $885,600.00 per year. Learn More on Juliette Berangere Audet's salary.

How do I contact Juliette Berangere Audet?

The corporate mailing address for Ms. Audet and other NewAmsterdam Pharma executives is TWO UNION SQUARE 601 UNION STREET SUITE 3200, SEATTLE WA, 98101. NewAmsterdam Pharma can also be reached via phone at 352062971 and via email at max.nowicki@frazierhealthcare.com. Learn More on Juliette Berangere Audet's contact information.

Has Juliette Berangere Audet been buying or selling shares of NewAmsterdam Pharma?

Juliette Berangere Audet has not been actively trading shares of NewAmsterdam Pharma in the last ninety days. Most recently, on Thursday, September 26th, Juliette Berangere Audet bought 1,104 shares of NewAmsterdam Pharma stock. The stock was acquired at an average cost of $15.70 per share, with a total value of $17,332.80. Following the completion of the transaction, the insider now directly owns 1,104 shares of the company's stock, valued at $17,332.80. Learn More on Juliette Berangere Audet's trading history.

Who are NewAmsterdam Pharma's active insiders?

NewAmsterdam Pharma's insider roster includes Juliette Audet (Insider), Michael Davidson (CEO), Johannes Kastelein (Insider), Louise Kooij (CAO), and James Topper (Director). Learn More on NewAmsterdam Pharma's active insiders.

Are insiders buying or selling shares of NewAmsterdam Pharma?

During the last twelve months, NewAmsterdam Pharma insiders bought shares 4 times. They purchased a total of 18,538 shares worth more than $369,041.40. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 832,206 shares worth more than $19,296,828.63. The most recent insider tranaction occured on March, 4th when Director James N Topper bought 4,005 shares worth more than $84,185.10. Insiders at NewAmsterdam Pharma own 19.5% of the company. Learn More about insider trades at NewAmsterdam Pharma.

Information on this page was last updated on 3/4/2025.

Juliette Berangere Audet Insider Trading History at NewAmsterdam Pharma

See Full Table

Juliette Berangere Audet Buying and Selling Activity at NewAmsterdam Pharma

This chart shows Juliette Berangere Audet's buying and selling at NewAmsterdam Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10k$0$10kTotal Insider BuyingTotal Insider Selling

NewAmsterdam Pharma Company Overview

NewAmsterdam Pharma logo
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Read More

Today's Range

Now: $23.34
Low: $23.12
High: $23.77

50 Day Range

MA: $21.90
Low: $17.53
High: $26.04

2 Week Range

Now: $23.34
Low: $15.19
High: $27.29

Volume

1,435,402 shs

Average Volume

491,525 shs

Market Capitalization

$2.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A